Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin Chessex A, Zanna C, Flaherty KT, Baselga J.

Clin Cancer Res. 2019 Feb 11. pii: clincanres.1959.2018. doi: 10.1158/1078-0432.CCR-18-1959. [Epub ahead of print]

PMID:
30745300
2.

Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.

Dagogo-Jack I, Robinson H, Mino-Kenudson M, Farago AF, Kamesan V, Iafrate AJ, Shaw AT, Lennerz JK.

J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30024-3. doi: 10.1016/j.jtho.2018.12.032. [Epub ahead of print]

PMID:
30660796
3.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.

Tanaka S, Luk S, Kiyokawa J, Onozato ML, Iafrate AJ, Shah K, Martuza RL, Rabkin SD, Batchelor TT, Cahill DP, Chi AS, Wakimoto H.

Sci Rep. 2019 Jan 15;9(1):139. doi: 10.1038/s41598-018-37437-2.

4.

Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.

Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Hobbs GS, Nardi V.

Hum Pathol. 2018 Dec 27. pii: S0046-8177(18)30476-3. doi: 10.1016/j.humpath.2018.11.022. [Epub ahead of print]

PMID:
30594750
5.

Implementing the DICOM Standard for Digital Pathology.

Herrmann MD, Clunie DA, Fedorov A, Doyle SW, Pieper S, Klepeis V, Le LP, Mutter GL, Milstone DS, Schultz TJ, Kikinis R, Kotecha GK, Hwang DH, Andriole KP, Iafrate AJ, Brink JA, Boland GW, Dreyer KJ, Michalski M, Golden JA, Louis DN, Lennerz JK.

J Pathol Inform. 2018 Nov 2;9:37. doi: 10.4103/jpi.jpi_42_18. eCollection 2018.

6.

Financially Effective Test-Algorithm to Identify an Aggressive, EGFR-amplified Variant of IDH-Wildtype, Lower-Grade Diffuse Glioma.

Bale TA, Jordan JT, Rapalino O, Ramamurthy N, Jessop N, DeWitt JC, Nardi V, Martinez-Lage Alvarez M, Frosch M, Batchelor TT, Louis DN, Iafrate AJ, Cahill DP, Lennerz JK.

Neuro Oncol. 2018 Nov 28. doi: 10.1093/neuonc/noy201. [Epub ahead of print]

PMID:
30496526
7.

Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays.

Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT, Montgomery SB, Nagarajan R, Portier BP, Routbort MJ, Smail C, Surrey LF, Vasalos P, Lazar AJ, Lindeman NI.

Arch Pathol Lab Med. 2018 Oct 30. doi: 10.5858/arpa.2018-0336-CP. [Epub ahead of print]

PMID:
30376374
8.

Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies.

Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS.

Oncologist. 2019 Feb;24(2):193-201. doi: 10.1634/theoncologist.2018-0152. Epub 2018 Oct 29.

PMID:
30373904
9.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

10.

Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.

Zhang ML, Kem M, Mooradian MJ, Eliane JP, Huynh TG, Iafrate AJ, Gainor JF, Mino-Kenudson M.

Mod Pathol. 2018 Oct 26. doi: 10.1038/s41379-018-0160-1. [Epub ahead of print]

PMID:
30367104
11.

Artificial Intelligence Approach for Variant Reporting.

Zomnir MG, Lipkin L, Pacula M, Meneses ED, MacLeay A, Duraisamy S, Nadhamuni N, Al Turki SH, Zheng Z, Rivera M, Nardi V, Dias-Santagata D, Iafrate AJ, Le LP, Lennerz JK.

JCO Clin Cancer Inform. 2018;2. doi: 10.1200/CCI.16.00079. Epub 2018 Mar 22.

12.

TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.

Williams EA, Miller JJ, Tummala SS, Penson T, Iafrate AJ, Juratli TA, Cahill DP.

Acta Neuropathol Commun. 2018 Oct 17;6(1):106. doi: 10.1186/s40478-018-0613-2.

13.

A Nanopore Sequencing-Based Assay for Rapid Detection of Gene Fusions.

Jeck WR, Lee J, Robinson H, Le LP, Iafrate AJ, Nardi V.

J Mol Diagn. 2019 Jan;21(1):58-69. doi: 10.1016/j.jmoldx.2018.08.003. Epub 2018 Sep 28.

PMID:
30273778
14.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
15.

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM.

Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17.

PMID:
30224342
16.

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

Farago AF, Taylor MS, Doebele RC, Zhu VW, Kummar S, Spira AI, Boyle TA, Haura EB, Arcila ME, Benayed R, Aisner DL, Horick NK, Lennerz JK, Le LP, Iafrate AJ, Ou SI, Shaw AT, Mino-Kenudson M, Drilon A.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00037. Epub 2018 Jul 23.

17.

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.

Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK.

Acta Neuropathol. 2018 Nov;136(5):779-792. doi: 10.1007/s00401-018-1899-7. Epub 2018 Aug 19.

PMID:
30123936
18.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16.

19.

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG.

Cancer Cell. 2018 Aug 13;34(2):242-255.e5. doi: 10.1016/j.ccell.2018.06.013.

PMID:
30107175
20.

Genotype-targeted local therapy of glioma.

Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT Jr, Barker FG 2nd, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8388-E8394. doi: 10.1073/pnas.1805751115. Epub 2018 Aug 6.

PMID:
30082399
21.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.

Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR.

Ann Oncol. 2018 Sep 1;29(9):1964-1971. doi: 10.1093/annonc/mdy242.

PMID:
30010763
22.

Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.

Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS.

Cancer Med. 2018 May 17. doi: 10.1002/cam4.1558. [Epub ahead of print]

23.

Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome.

Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Hartford NM, Oliva E, Chung DC.

Cancer. 2018 Aug 1;124(15):3145-3153. doi: 10.1002/cncr.31534. Epub 2018 May 11.

PMID:
29750335
24.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT.

Nat Commun. 2018 Apr 16;9(1):1474. doi: 10.1038/s41467-018-03905-6.

25.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT.

Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12.

PMID:
29650534
26.

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.

Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055.

PMID:
29553955
27.

MET Amplification in Esophageal Squamous Carcinoma.

Michaels PD, Robinson H, Nardi V, Iafrate AJ, Le L, Lennerz JK.

Int J Surg Pathol. 2018 Dec;26(8):731-732. doi: 10.1177/1066896918764301. Epub 2018 Mar 19. No abstract available.

PMID:
29552946
28.

Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer.

Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB.

Cancer Discov. 2018 Apr;8(4):417-427. doi: 10.1158/2159-8290.CD-17-1227. Epub 2018 Feb 5.

PMID:
29431697
29.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23.

30.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

PMID:
29373100
31.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

32.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

PMID:
29242214
33.

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A.

Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.

PMID:
29236940
34.

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.

DeWitt JC, Jordan JT, Frosch MP, Samore WR, Iafrate AJ, Louis DN, Lennerz JK.

Neuro Oncol. 2017 Nov 29;19(12):1640-1650. doi: 10.1093/neuonc/nox120.

35.

Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.

Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Tanguturi S, Goyal L, Murphy JE, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Tanabe KK, Ferrone CR, Ryan DP, Iafrate AJ, DeLaney TF, Zhu AX.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx031.

PMID:
28954285
36.

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W Jr, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.

Int J Cancer. 2017 Dec 1;141(11):2348-2358. doi: 10.1002/ijc.30929. Epub 2017 Aug 26.

37.

GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Ritterhouse LL, Vivero M, Mino-Kenudson M, Sholl LM, Iafrate AJ, Nardi V, Dong F.

Mod Pathol. 2017 Dec;30(12):1720-1727. doi: 10.1038/modpathol.2017.88. Epub 2017 Aug 4.

38.

Recurrent and functional regulatory mutations in breast cancer.

Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G.

Nature. 2017 Jul 6;547(7661):55-60. doi: 10.1038/nature22992. Epub 2017 Jun 28.

39.

The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.

Tateishi K, Higuchi F, Miller JJ, Koerner MVA, Lelic N, Shankar GM, Tanaka S, Fisher DE, Batchelor TT, Iafrate AJ, Wakimoto H, Chi AS, Cahill DP.

Cancer Res. 2017 Aug 1;77(15):4102-4115. doi: 10.1158/0008-5472.CAN-16-2263. Epub 2017 Jun 16.

40.

KIF13B-NRG1 Gene Fusion and KRAS Amplification in a Case of Natural Progression of Lung Cancer.

Xia D, Le LP, Iafrate AJ, Lennerz J.

Int J Surg Pathol. 2017 May;25(3):238-240. doi: 10.1177/1066896917693092.

PMID:
28391773
41.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, Gillespie SM, Dionne D, Luo CC, Ravichandran H, Mylvaganam R, Mount C, Onozato ML, Nahed BV, Wakimoto H, Curry WT, Iafrate AJ, Rivera MN, Frosch MP, Golub TR, Brastianos PK, Getz G, Patel AP, Monje M, Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A, Suvà ML.

Science. 2017 Mar 31;355(6332). pii: eaai8478. doi: 10.1126/science.aai8478.

42.

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK.

NPJ Precis Oncol. 2017 Mar 20;1(1):5. doi: 10.1038/s41698-017-0009-y. eCollection 2017.

43.

Primitive Neuroectodermal Tumors of the Female Genital Tract: A Morphologic, Immunohistochemical, and Molecular Study of 19 Cases.

Chiang S, Snuderl M, Kojiro-Sanada S, Quer Pi-Sunyer A, Daya D, Hayashi T, Bosincu L, Ogawa F, Rosenberg AE, Horn LC, Wang L, Iafrate AJ, Oliva E.

Am J Surg Pathol. 2017 Jun;41(6):761-772. doi: 10.1097/PAS.0000000000000831.

44.

Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases.

Arnason T, Borger DR, Corless C, Hagen C, Iafrate AJ, Makhlouf H, Misdraji J, Sapp H, Tsui WM, Wanless IR, Zuluaga Toro T, Lauwers GY.

Am J Surg Pathol. 2017 Apr;41(4):499-505. doi: 10.1097/PAS.0000000000000773.

PMID:
28266931
45.

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PM.

J Mol Diagn. 2017 Mar;19(2):313-327. doi: 10.1016/j.jmoldx.2016.10.007. Epub 2017 Feb 7.

46.

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.

Lin JJ, Ritterhouse LL, Ali SM, Bailey M, Schrock AB, Gainor JF, Ferris LA, Mino-Kenudson M, Miller VA, Iafrate AJ, Lennerz JK, Shaw AT.

J Thorac Oncol. 2017 May;12(5):872-877. doi: 10.1016/j.jtho.2017.01.004. Epub 2017 Jan 11.

47.

A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome.

Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Chung DC.

Mod Pathol. 2017 Mar;30(3):440-447. doi: 10.1038/modpathol.2016.211. Epub 2017 Jan 6.

48.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX.

Cancer Discov. 2017 Mar;7(3):252-263. doi: 10.1158/2159-8290.CD-16-1000. Epub 2016 Dec 29.

49.

IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.

Chiang S, Weigelt B, Wen HC, Pareja F, Raghavendra A, Martelotto LG, Burke KA, Basili T, Li A, Geyer FC, Piscuoglio S, Ng CK, Jungbluth AA, Balss J, Pusch S, Baker GM, Cole KS, von Deimling A, Batten JM, Marotti JD, Soh HC, McCalip BL, Serrano J, Lim RS, Siziopikou KP, Lu S, Liu X, Hammour T, Brogi E, Snuderl M, Iafrate AJ, Reis-Filho JS, Schnitt SJ.

Cancer Res. 2016 Dec 15;76(24):7118-7129. Epub 2016 Oct 20.

50.

Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma.

Tirosh I, Venteicher AS, Hebert C, Escalante LE, Patel AP, Yizhak K, Fisher JM, Rodman C, Mount C, Filbin MG, Neftel C, Desai N, Nyman J, Izar B, Luo CC, Francis JM, Patel AA, Onozato ML, Riggi N, Livak KJ, Gennert D, Satija R, Nahed BV, Curry WT, Martuza RL, Mylvaganam R, Iafrate AJ, Frosch MP, Golub TR, Rivera MN, Getz G, Rozenblatt-Rosen O, Cahill DP, Monje M, Bernstein BE, Louis DN, Regev A, Suvà ML.

Nature. 2016 Nov 10;539(7628):309-313. doi: 10.1038/nature20123. Epub 2016 Nov 2.

Supplemental Content

Loading ...
Support Center